Research is progressing with novel biomarkers, therapies, and diagnostics addressing cardiovascular and metabolic conditions. Studies identified imidazole propionate (ImP), a gut microbiota metabolite, as a driver and therapeutic target in atherosclerosis. The American Heart Association invested in Auxira Health, deploying virtual clinical teams to alleviate cardiologist burnout and expand patient access. New software by Caranx Medical received FDA clearance to guide transcatheter aortic valve replacement (TAVR) procedures. Separately, studies revealed proteins modulating inflammation and disease pathways, and cell-free therapies show promise for heart attack recovery, potentially offering manufacturable alternatives to cell therapies.